1,2,3,4,6-Penta-O-galloyl-beta-D-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor.
SCIE
SCOPUS
- Title
- 1,2,3,4,6-Penta-O-galloyl-beta-D-glucose blocks endothelial cell growth and tube formation through inhibition of VEGF binding to VEGF receptor.
- Authors
- Lee, SJ; Lee, HM; Jie, ST; Lee, SR; Mar, W; Gho, YS
- Date Issued
- 2004-05-10
- Publisher
- ELSEVIER SCI IRELAND LTD
- Abstract
- Tumor angiogenesis is a critical step for the growth and metastasis of solid tumors. Vascular endothelial growth factor (VEGF) is the most important angiogenic molecule associated with tumor-induced neovascularization. VEGF exerts its activity through binding to its receptor tyrosine kinase, KDR/Flk-1, expressed on the surface of endothelial cells. From the screening of medicinal plants, we have identified 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) from the roots of Paeonia lactiflora that inhibited the binding of VEGF to KDR/Flk-1. PGG efficiently blocked VEGF-induced human umbilical vein endothelial cell proliferation and the growth of immortalized human microvascular endothelial cells, but did not affect the growth of HT1080 human fibrosarcoma and DU-145 human prostate carcinoma cells. PGG also blocked VEGF-induced capillary-like tube formation of endothelial cell on Matrigel. Our results suggest that PGG could be a candidate for developing anti-angiogenic agent. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
- Keywords
- 1,2,3,4.6-penta-O-galloyl-beta-D-glucose; vascular endothelial growth factor; KDR/Flk-1; angiogenesis; cancer; TUMOR-GROWTH; CANCER-THERAPY; IN-VITRO; ANGIOGENESIS; METASTASIS; VASCULOGENESIS; EXPRESSION; LETHALITY; MITOGEN; FLK-1
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/28389
- DOI
- 10.1016/J.CANLET.200
- ISSN
- 0304-3835
- Article Type
- Article
- Citation
- CANCER LETTERS, vol. 208, no. 1, page. 89 - 94, 2004-05-10
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.